Mr. Speaker, I thank the gentleman from Texas for yielding me this time. This is a very important topic. I am a cancer survivor myself, but I think every family in America has been touched by serious illness, and the NIH can help if it is…
Mr. Speaker, I thank the gentleman from Texas for yielding me this time. This is a very important topic. I am a cancer survivor myself, but I think every family in America has been touched by serious illness, and the NIH can help if it is properly funded. We are very grateful for the increases in the past. I celebrate the leadership of the gentleman from Ohio; he is a great Member of this body. But I worry that others in his party who call themselves compassionate conservatives have left out the compassionate part.
To freeze the NIH budget at a time like this does serious damage to the research efforts that are going on all across this country, literally harming the futures of so many of our citizens. It is not the gentleman's fault. He has done the best that he can.
We all know that in this nonbinding motion that we are all about to vote for, it will really amount to very little change in that budget. We can and must do more. We must influence the President's budget- making process right now for his budget for next fiscal year. We need to make sure that we have no more freezes like this, no more inadequate increases, because the need is too great, whether it is cancer or heart or stroke or ALS or cystic fibrosis and a myriad of other diseases. People do not have the time to wait.
So it is very important that we tackle these issues. I would hope that the gentleman, as he votes for this nonbinding motion to instruct, and his colleagues, will do more than just put that vote up on the board and pretend that they are for a big increase, because we all know that in the President's budget this last year, there was not a big increase. There was not really much more than a freeze, and we have to do better than that.
So this is a time for us to really dig deep, to do the quiet, behind- the-scenes work that is necessary to make sure that our NIH budget genuinely increases to meet the terrific need, not only in our country, but around the world, because as the gentleman knows, we are inventing the cures for diseases around this world.
[From the Tennessean.com, Nov. 7, 2003]
Representative Jim Cooper: Don't Let Congressional Budget Cuts Slow the
War Against Cancer
(By Representative Jim Cooper)
Patty Corlew lives on a quiet street in Mt. Juliet. She's a
wife and mother. She works part-time. She helps out at Boy
Scouts and is someone folks describe as a solid friend and
good neighbor. Patty Corlew is not someone you'd likely
expect to be a protestor. Fortunately, you'd be wrong about
Patty Corlew.
``My boys were almost 2 and almost 6 when I was diagnosed
with breast cancer. Thanks for these last nine years. I only
wish my friend Mary and Elizabeth and others could have
shared them with me and watched their children grow and
become grandmothers like I hope to become. Please find a
cure.''
Patty Corlew is speaking out. She's added her name and her
story to the growing list of Middle Tennessee-area cancer
survivors who are concerned about the proposed level of
funding for the National Institutes of Health (NIH) currently
pending in Congress.
Those of us fortunate to live in Middle Tennessee don't
have to look far to see the potential impact of a slowdown in
NIH funding. Nashville is home to two of the leading medical
research institutions working in partnership with NIH and its
National Cancer Institute (NCI).
At the Vanderbilt-Ingram Cancer Center, a team led by Dr.
Ray DuBois was the first to establish the link between
colorectal tumors and an enzyme known as COX-2. Their
findings helped explain why people who took large quantities
of aspirin or drugs like ibuprofen over long periods of time
had a lower incidence of colorectal cancer. Dr. DuBois is now
the leader of a national study exploring whether COX-2
inhibitors might be used to prevent colorectal cancer as
well as a variety of other cancers.
Meharry Medical College recently launched a long-term study
of racial disparities in breast cancer. Women from minorities
are more likely to die of breast cancer today even though
they are less likely to get the disease. According to Dr. Ana
Grau, cancer surgeon and director of The Breast Health Center
at Metro General Hospital at Meharry, the center is
determined to improve breast cancer survival rates for all
women.
In another study, Vanderbilt-Ingram and Meharry are working
together to answer one simple but important question: Why are
African Americans, and all people in the South,
at greater risk of developing and dying from cancer than
other ethnic or regional groups? The NIH-supported study will
track more than 100,000 participants over five years to
determine what lifestyle factors may be related to higher
cancer rates for minorities and all residents in our region.
As these examples indicate, NIH is providing help and hope
to millions of Americans today. Without the appropriate
funding, however, future discoveries like these may be
threatened.
In each of the past five years, NIH funding has increased
by 14-15%. Last year, during congressional hearings, NIH
leadership said the current pace of medical breakthroughs
could only be maintained if NIH funding continues to grow at
a level of 8-10%. Yet the House and Senate Conference
Committee is expected to support the Bush Administration's
NIH request: an increase of just 2.7%.
Like Patty Corlew, I am a cancer survivor. I was fortunate
to discover my cancer early. And I am blessed to live in a
community where cutting-edge cancer research and treatment is
something we almost take for granted.
The examples described here of research being conducted at
Vanderbilt-Ingram and Meharry are only three out of many
promising studies currently underway at each institution. And
Vanderbilt-Ingram and Meharry are not alone in working at the
frontier of cancer research. More than 80% of NIH funding now
goes to support research conducted at universities around the
country.
In the next few weeks, Congress will be asked to decide the
future direction of NIH work, whether the pace of disease
exploration should continue at the aggressive level of recent
years. In these tough economic times, every budget decision
must be evaluated carefully. We must consider not only costs,
but potential return on each taxpayer dollar we commit.
How do you measure the value of good health and quality of
life?
As a member of the House Budget Committee, I am very
concerned about the current trend in government spending. I
strongly believe we cannot continue to ignore the rising
deficit. But I also believe we cannot turn our backs on the
progress currently being made in medical research. On the
issue of NIH fund, I stand with Patty Corlew.